Tue01312023

Last updateThu, 29 Dec 2022 2pm

Back You are here: Inicio Biology & biomedicine

Dressings made of biologically active nanocellulose for treating corneal wounds

Scientists at the ICMAB-CSIC have published the firsts results of this innovative ophthalmological treatment in the Biomaterials Science magazine. Bacterial nanocellulose is more affordable and easy to preserve than current treatments, and it will be impregnated with growth factors to accelerate corneal regeneration. The research is developed in close collaboration with the Barraquer Ophthalmology Centre in Barcelona, which supports this project from a clinical perspective.

Read more ...

A radiotracer to identify and see cholesterol accumulated on vessel walls

A new peptide-based radiotracer has been designed to identify LDL-cholesterol retained and accumulated on the vascular wall of arteries, which can be seen in the very early stages of the disease. The CSIC and the Hospital de Sant Pau are leading this project, which recently was selected in the latest call for grants from the BBVA Foundation for Scientific Research Teams in Biomedicine.

Read more ...

Monitoring mitochondria of living cells to diagnose cancer and other diseases

Scientists from the Institute of Organic Chemistry of the CSIC in Madrid have developed the first fluorescent probe to be introduced in the mitochondria to monitor its function in living cells. A discovery that can have applications in the diagnosis and treatment of pathologies such as cancer, heart disease or diabetes, as well as other mitochondrial diseases.

Read more ...

Cell stimulation device for use in medical prostheses

Scientists at the Microelectronics Institute of Barcelona have developed a device based on nanogenerators for the electrical stimulation of cells, without the need of bulky electrodes or instruments. The advancement has applications in health for bone regeneration in prostheses or the rehabilitation of muscular atrophy.

Read more ...

Synthetic peptides for fighting metastasis related to the interleukin receptor IL13Rα2

The CSIC has developed a peptide capable of inhibiting the signaling of interleukin 13 mediated by the IL13Rα2 alpha receptor, one of the pathways that contribute metastasis according to recent studies. The synthetic peptide, alone or encapsulated, could be used for the control of metastasis of colon cancer and other tumours such as glioblastoma, as well as in pathologies such as asthma, atopic dermatitis or fibrosis, related to the same receptor, although more assays are required to confirm its efectivity in humans.

Read more ...